← Evidence map

TrialCancer research and treatment2026

A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906).

Kwai Han Yoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906). | OpenQuestion